Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

AI Summary

The Phase 2 results for Diranersen (BIIB080) indicate a significant reduction in tau pathology and cognitive benefits for early Alzheimer's patients. This study marks a pivotal moment in Alzheimer's research.

The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker ...